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ABSTRACT 
 
Gastric cancer (GC) is still one of the leading causes of cancer-related deaths 
worldwide and high mortality rate is mainly due to late-stage diagnosis. New 
insights show that epigenetic alterations contribute significantly to the 
development and progression of GC and if nowadays the role of somatic 
mutations as drivers of carcinogenesis in the alimentary tract is well 
established, the importance of gene silencing by epigenetic mechanisms is 
increasingly recognized. Gastrokine1 (GKN1) is a highly expressed stomach 
protein important for maintaining the physiological function of the gastric 
mucosa. GKN1 is down-regulated in gastric tumor tissues and derived cell 
lines so it has recently emerged as a potential biomarker for gastric cancer. It 
has also been demonstrated that GKN1 expression induces apoptosis in 
gastric cancer cells thus suggesting a possible role of the protein as tumor 
suppressor. The mechanism by which GKN1 gene is inactivated in GC 
remains still unknown, so here I have investigated on the possible causes of 
GKN1 gene silencing in order to determine if epigenetic mechanisms could 
also contribute to its down-regulation. To these aim, chromatin 
immunoprecipitation (ChIP) assays for the repressive trimethylation of 
histone 3 at lysine 9 (H3K9triMe) and its specific histone-lysine N-
methyltransferase (SUV39H1) were performed on biopsies of normal and 
tumor human gastric tissues. The results showed that GKN1 downregulation 
in gastric cancer tissues is associated with high levels of  H3K9triMe and 
with the recruitment of SUV39H1 on GKN1 promoter, suggesting the 
presence of an epigenetic transcriptional complex that negatively regulates 
GKN1 expression in gastric tumor. 
It was also investigated whether underacetylation might contribute to GKN1 
transcriptional inhibition using TSA to increase general histone acetylation. 
The results showed that inhibition of HDACs leads to GKN1 restoration at 
transcriptional level, but no at traslational level. These findings led to 
hypothesize that a second regulatory block occurs at translational level, 
perhaps by mechanisms mediated by microRNAs (miRNAs), resulting in 
translational repression and gene silencing. So, the possible involvment of 
miRNAs in this process was investigated. The results demostrated that GKN1 
3’UTR was a direct target of hsa-miR-544a and miR-1245b-3p and showed 
an increase of miR-544a expression in the gastric cancer cell lines after TSA 
treatment.  
The up-regulation of miR-544a could be the cause of the GKN1 
translational repression, thus suggesting its potential role as biomarker and 
therapeutic target in GC patients. 
These findings indicate that epigenetic mechanisms leading to the 
inactivation of GKN1 play a key role in the multi-step process of gastric 
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carcinogenesis and would provide an essential starting point for the 
development of new therapeutic strategies based on epigenetic targets for 
alternatives gene. 
 
 
Abbreviations 
AMP18, 18 kDa antrum mucosal protein; ChIP, chromatin 
immunoprecipitation; DMSO, dimethyl sulfoxide; DNMT1, DNA (cytosine-
5)-methyltransferase 1; EZH2, enhancer of zeste homolog 2; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; GC, gastric cancer; GKN1, 
gastrokine 1; G6PD, glucose-6-phosphate dehydrogenase; EBNA1, Epstein-
Barr nuclear antigen 1; EBV, Epstein- Barr virus; HAT, histone 
acetyltransferases; HDAC, histone deacetylase; H3K9triMe, trimethylation of 
Histone 3 at lysine 9; IM, intestinal metaplasia; PIPES, 1,4-
piperazinediethanesulfonic acid; PMSF, phenylmethylsulfonyl fluoride; 
ROS, reactive oxygen species; RNU6, U6 Small nucleolar RNA; Tip60, 
Histone acetyltransferase; TSA, trichostatin A; SUV39H1, Histone-lysine N-
methyltransferase; 3’UTR, 3’-untranslated regions. 
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1. INTRODUCTION 
 
1.1 Gastric cancer 
Gastric cancer (GC), despite its declining incidence rate, is still the fourth 
most common cancer and the second cause of cancer-related death 
worldwide. Most patients are typically asymptomatic and diagnosed at an 
advanced stage, thus GC continues to be a highly aggressive malignancy that 
is associated with poor prognosis and a low survival rate [1, 2].  
According to the classification criteria developed by Lauren in 1965 [3], 
GC is frequently divided into the intestinal type and the diffuse type, each 
having different epidemiological and pathophysiological features. The 
intestinal-type generally evolves through a relatively well-defined sequence 
of histological lesions, namely nonatrophic gastritis, chronic atrophic 
gastritis, intestinal metaplasia, and dysplasia. The diffuse subtype has instead 
a poorer prognosis and develops from normal gastric epithelium through 
unknown genetic and morphological events. The intestinal type is more 
common in males and older age groups, while the diffuse type is more 
common in younger age groups; the incidence has no association with sex 
difference [4]. 
The etiology of GC is multifactorial including environmental, genetic and 
infectious factors [5-7]. Multiple evidence demonstrated the important role of 
Helicobacter pylori (H. pylori) infection in the development of GC [8-10]. In 
fact, exposure of gastric epithelial cells to the bacterium determines the 
release of cytokines and reactive oxygen species (ROS) leading to the 
inflammatory and immune response of the stomach epithelium, that in turn 
may cause genetic alterations and an increased risk of developing GC. 
Although the molecular pathways and histologic changes involved in 
progression to cancer are less characterized, GC, as other neoplasias, is 
thought to result from a combination of environmental factors and the 
accumulation of genetic and epigenetic alterations, which affect, tumor 
suppressor genes or oncogenes.  
The understanding the molecular pathophysiology of GC and the 
identification of novel prognostic and diagnostic biomarkers are necessary to 
reduce the mortality rates through cancer screenings in high-risk populations, 
to increase early diagnosis, and to develop new target therapies.  
 
1.2 Gastrokine 1 
In order to search for possible informative biomarkers for GC, a new protein 
named gastrokine 1 (GKN1) was identified by proteomic approach. 
Gastrokine1 protein, previously known as 18 kDa antrum mucosal protein 
(AMP-18) was subsequently called by the "Human Gene Nomenclature 
Committee" GKN1 for its tissue-specific expression and its highly conserved 
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presence in the gastric mucosa of many mammalian species [11- 14]. The 
gene coding for GKN1 (CA11, accession number: BK0017373) is located in 
a 6 kb region of the chromosome 2p13 and contains 6 exons separated by 
relatively short introns that encode small (from 181- to 184-amino acid) 
proteins containing a conserved central structural BRICHOS domain of about 
100 amino acids including two conservative cysteine residues most likely 
involved in disulfide bridges; a COOH-terminal segment, showing 
considerable divergence between the GKN1 paralogs and the hydrophobic 
NH2-terminal signal peptide, that acts as a transmembrane anchor and/or 
signal peptide; the processing of which is predicted to generate about 160 
mature amino acid proteins [15].   
Molecular studies on the BRICHOS domain function have suggest that it 
has a range of possible roles, including intracellular trafficking, pro-peptide 
processing, chaperone function and secretion. The hydrophobic region and 
BRICHOS domain in GKN1 seem to suppress GC cell growth, reduce cell 
viability, proliferation and colony formation in AGS cells. It might be the 
main functional domain for the tumor suppressor activity [16, 17]. 
GKN1 is a secretory protein that tends to localize within the granules just 
under the apical plasma membrane [18, 19], and its expression is confined to 
the gastric epithelium, except for trace levels in the placenta [19]. The protein 
is highly expressed in the gastric mucosa of healthy individuals, but markedly 
down-regulated in samples derived from H. Pylori infected patients [20]. 
Furthermore, GKN1 was also found to be down-regulated or completely 
absent in GC tissues [21, 22]. 
Although the biological function of this protein is currently unknown, a role 
in cell proliferation and differentiation has been hypothesized, as well as the 
potential involvement in the replenishment of the surface lumen epithelial 
cell layer and the maintaining of mucosal integrity [23, 24]. After injury of 
the gastric mucosa, restoration may occur very rapidly in the presence of 
GKN1 [25]. In contrast, if the protein is down regulated, the repair process 
may be hampered. In fact, application of GKN1 to gastrointestinal cells 
promoted epithelial restoration by increasing accumulation of specific tight 
and adherens junction proteins thus promoting stabilization of actin network 
[18]. All these data show that GKN1 has a very important role in 
maintenance of gastric mucosal homeostasis and its early down regulation 
may lead to a defect in the gastric mucosal barrier, rendering gastric mucosa 
subject to exposure to carcinogens and eventually evoke subsequent genetic 
alterations of tumor suppressor genes or oncogenes involved in gastric 
carcinogenesis. GKN1 can also induce apoptosis and senescence. In fact 
restoration of GKN1 expression resulted in cell cycle arrest at the G1/s or 
G2/M phases caused by a down regulation of positive cell cycle regulators, 
including CDK4, cyclin D1, E2F, cdc25 and cyclin B, and an up regulation 
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of negative cell cycle regulators, including p16 and p21 [26]. Furthermore 
our group investigated the effect of GKN1 on gastric cell line. The 
overexpression of the protein in AGS and MKN28 cells activated the 
expression of Fas receptor, while treatment with an anti-Fas antibody 
significantly increased apoptosis [27]. Moreover, treatment of tumor cells 
with recombinant human GKN1 reduced the proliferation of AGS cells 
compared with human embryonic kidney cells (HEK 293) and non-gastric 
cancer cells (H1355) [28]. Recent evidence has also demonstrated that GKN1 
is involved in gastric mucosal inflammation by regulating production of 
inflammatory mediators, including NF-kB, COX-2 and cytokines and inhibits 
the carcinogenetic potential of H. pylori trough the direct binding to CagA at 
the extracellular level and increasing the expression of antioxidant enzymes 
at the intracellular level [29]. Subsequent study found that GKN1 is involved 
also in the epithelial mesenchymal transistion, a process observed in response 
to injury, organ fibrosis and cancer. In particular the recovery of GKN1 
expression suppresses cell migration and invasiveness abrogating the 
expression of PI3K/akt pathway proteins, concomintant with the re-
expression of E-cadherin [30]. These data suggest that GKN1 may be a 
gastric specific tumor suppressor. GKN1 could also be considered a 
biomarker for GC because individuals with a lower expression of the protein 
have an increased risk of developing gastric diseases.  
 
1.3 Epigenetic and gastric cancer 
GC is a very complex and heterogeneous disease, and although much has 
been learned about the different genetic changes that eventually lead to its 
development, the detailed mechanisms still remain unclear. Malignant 
transformation of gastric cells is the consequence of a multistep process 
involving different genetic and epigenetic changes in numerous genes in 
combination with host genetic background and environmental factors [31].    
Increasing evidence suggests that epigenetic changes play a key role in 
cancer development, including gastric cancer [32].    
Epigenetics refers to a number of modifications in the chromatin structure 
that affect gene expression without altering the primary DNA sequence, and 
these changes lead to transcriptional activation or silencing of the gene. 
Epigenetic regulation of chromatin is a normal and vital process of cell 
differentiation and development. It explains the ability of stem cells from a 
single origin to differentiate into all of the necessary cells of the human body; 
then remain differentiated without reverting back to a stem cell or other cell 
type. In tumorigenesis however, there is dysregulation of the physiologic 
epigenetic process, and this contributes to the development of malignancy.  
At present, the most important epigenetic mechanisms involved in the 
carcinogenic process include DNA methylation, histone modification and 
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non-coding RNAs, mainly microRNAs.  DNA methylation, that consists in 
the addition of a methyl group to cytosine residues (5mC) in CpG 
dinucleotides, contributes to cancer through DNA hypo-or hypermethylation. 
It has been observed that almost half of the tumor suppressor genes that 
causes familial cancers through mutations are also inactivated by promoter 
hypermethylation in sporadic cancers. The methylation changes that occur 
within CpG islands, which are present in about 70% of all mammalian 
promoters, plays an important role in transcriptional regulation, and it is 
commonly altered during malignant transformation [33]. Recent studies have 
describe a number of genes that are silenced by hypermethylation in gastric 
cancer associated with H. pylori or Epstein Barr virus infection (EBV) the 
most important of which include: cycle regulators p16(INK4a), p14(ARF) 
and APC; DNA-repair genes, hMLH1, BRCA1 and MGMT; the cell 
adherence gene E-cadherin [34, 35]. Recent research focused on exploring 
the role of hystone modification in the pathogenensis of gastric cancer. 
Histone modifications, which have been recently recognized to generate a 
'histone code' that affects chromatin structure and gene expression, also play 
an important role in the establishment of gene silencing during 
tumorigenesis. Histones are evolutionarily highly conserved proteins 
characterized by an accessible aminoterminal tail and a histone fold domain 
that mediates interactions between histones to form the nucleosome scaffold. 
The N-terminal of histone polypeptides are modified by post-translational 
modifications, including methylation, acetylation, phosphorylation, 
ribosylation, ubiquitination, sumoylation, carbonylation and glycosylation. 
Acetylation and methylation of histones H3 and H4 seem to be the most 
widespread and functionally important modifications, playing a major role in 
the regulation of gene expression and they are also the only modification that 
have been clinically associated with pathological epigenetic disruption in 
cancer cells. The acetylation and deacetylation of key lysine residues of 
histone H3 and H4 are controlled by histone acetyltransferases and histone 
deacetylases (HDACs). 
Transcription becomes active when histones are acetylated by histone 
acetyltransferases (HAT), silenced when histones are deacetylated. The other 
modification includes methylation of arginine and lysine residues of histones. 
This methylation is catalyzed by histone methyltranferase (HMT) and, in 
general, lysine methylation at H3K9, H3K27 and H4K20 is associated with 
gene silencing, whereas methylation at H3K4, H3K36 and H3K79 is 
associated with gene activation. Recent studies identified candidate genes 
with significant differences in H3K27triMe in gastric cancer samples 
compared to adjacent non-neoplastic gastric tissues [36]. These genes 
included oncogenes, tumor suppressor genes, cell cycle regulators, and genes 
involved in cell adhesion. It has also been reported that methylation of 
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histone H3 plays an important role in carcinogenesis by silencing tumor 
suppressor genes [37]. Park et al. [38] observed global histone modification 
patterns using immunohistochemistry and reported that the trimethylation of 
H3K9 positively correlates with tumor stage and lymphovascular invasion in 
gastric cancer [38]. They also observed that the level of H3K9triMe was 
correlated with patient survival, because stronger methylation corresponded 
to a worse prognosis and intermediate methylation to an intermediate 
prognosis. On the other hand, the acetylation of histone, which occurs mostly 
from lysine residues of N-terminal domains, is known to be associated with 
transcriptional activation. The acetylation of histone H3 at K9 has been 
shown to be associated with a poorly differentiated or diffuse type of 
histology [38]. Histone H4 acetylation is reduced in gastric cancer compared 
to normal mucosa. The reduction of histone H4 acetylation correlates with a 
more advanced stage, deeper invasion and a greater extent of lymph node 
metastasis [39]. 
Deacetylation of histones may also be due to the activity of histone 
deacetylase (HDAC), responsible for removing the acetyl group to lysine 
residues. Aberrant histone deacetylation in gastric cancer lead to chromatin 
condensation and transcriptional inactivation of key genes important for 
normal gastric cells regulation. Deregulation of HADC activity has been 
strongly implicated in aberrant gene silencing and tumorigenesis. In fact 
HDAC has been reported to be up regulated in 17 of 25 gastric carcinomas 
and its expression is associated with aggressive behavior of primary gastric 
[40]. The class III HDACs play an important role in cell survival via 
deacetylation of key cell cycle and apoptosis regulatory molecules including 
p53 and Rb [40-42]. Histone H3 in the p21(WAF1/CIP1) promoter is 
hypoacetylated in gastric cancer; this hypoacetylation is associated with 
reduced p21(WAF1/CIP1) expression in gastric cancer specimens. Treatment 
of gastric carcinoma cell lines with HDAC inhibitor, trichostatin A, increases 
the acetylation level and restores p21(WAF1/CIP1) expression [43].  
Aberrant DNA methylation and histone deacetylation are also linked to the 
silencing of the SLC5A8 gene in gastric cancer [44]. SLC5A8 is a sodium co-
transporter, solute carrier family 5 member 8 gene and a putative tumor 
suppressor. Aberrant methylation of SLC5A8 gene is detected in both cell 
lines and in primary gastric cancers and acetylation of histone H3 correlates 
directly with SLC5A8 expression and inversely with DNA methylation. 
Recently, microRNA have emerged as molecular regulators that can have 
key roles in pathogenesis and progression of different malignancies, 
including gastric cancer. miRNAs are a class of small non-coding RNAs (19–
25 nucleotides) that act as important epigenetic players in many cellular 
processes, such as differentiation, proliferation and apoptosis, exerting a great 
influence in cancer pathogenesis [45, 46].   
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The mature miRNAs act as post-transcriptional regulators interacting with 
the 3’-untranslated regions (3’UTR) of the target transcripts and resulting in 
either mRNA degradation or inhibition of translation. Changes in miRNA 
expression profiles have been observed in a variety of human tumors, 
including gastric cancer [47]. 
Further studies demonstrated that miRNAs may function as tumor 
suppressors and oncogenes. These findings have shown great potential of 
miRNAs as a novel class of therapeutic targets [47]. In addition, it was found 
that some miRNAs were directly involved in patients with gastric cancer, 
including prognosis prediction, treatment selection, and in the search for 
unknown primary sites. 
All these findings suggest that epigenetic pathways play a significant role 
in gastric cancer because alteration of both methylation and acetylation of 
histones or the involvment of miRNA may give rise to the expression of 
oncogene and silence of tumor suppressors in cancer cells. Whereby a greater 
understanding of epigenetics and the therapeutic potential of intervention into 
these processes is necessary to help gastric cancer treatment. 
 
1.4 GKN1 inactivation 
Althougt it is well know that GKN1 expression is undetected in gastric 
tumors, the molecular mechanisms underlying its inactivation remain unclear. 
Recently, Yoon et al. 2011 [48] investigated this aspect in a sample group of 
81 gastric carcinomas and 40 gastric adenomas [48]. No mutation was 
detected in gastric tumors and hyper-methylation of the GKN1 promoter was 
only observed in two tumors, whereas DNA copy number and GKN1 mRNA 
levels were significantly decreased in all GC samples. More recently, the 
Epstein–Barr nuclear antigen 1 (EBNA1) protein was reported to directly 
bind GKN1 and GKN2 promoters [49]. Treatment of AGS-Epstein–Barr virus 
(EBV) and AGS-EBNA1 cell lines with 5' azacytidine showed that GKN1 
and GKN2 were transcriptionally silenced by DNA methylation, and that 
latent EBV infection further reduced GKN1 and GKN2 expression in AGS 
cells. EBNA1 depletion by small interfering RNA partially alleviated this 
repression. However, the ectopic expression of EBNA1 slightly increased 
GKN1 and GKN2 basal mRNA levels, but reduced their responsiveness to 
demethylating agents. These findings indicated that EBNA1 contributes to 
the transcriptional complex and epigenetic deregulation of GKN1 and GKN2 
tumor suppressor genes in EBV-positive GC. These studies indicate that 
epigenetic modifications play an important role in the initiation and 
progression of cancer and may in part explain the mechanism of GKN1 gene 
silencing in the early stages of tumorigenesis. 
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2. AIM  
Although these studies suggest that epigenetic modifications are involved in 
the deregulation of GKN1 in GC, no investigation on histone modifications or 
the recruitment of histone-modifying enzymes and GKN1 co-repressors in 
GC have yet been done. Therefore, in the present study, we attempted to 
clarify whether epigenetic mechanisms are associated with GKN1 silencing 
in GC and to determine whether this event might be involved in the 
development and progression of GC. 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
Dulbecco’s modified Eagle’s medium (DMEM-F12) and fetal bovine serumz 
(FBS) were purchased from Cambrex (Rutherford, NJ, USA). Mouse GKN1 
monoclonal antibody (M01), clone 2E5, was purchased from Abnova (Taipei, 
Taiwan). Rabbit monoclonal to Histone H3 (tri methyl K9) [ab8898] and to 
HDAC1 [ab109411] antibodies were from Abcam (Cambridge, MA, USA), 
mouse SUV39H1 (clone MG44) [05–615] and rabbit acetyl-Histone H3 [06–
599] antibodies were from Millipore (Temecula, CA, USA). DMSO and 
Trichostatin A (TSA) were from Sigma (Milan, Italy). Rabbit GAPDH 
monoclonal (glyceraldehyde-3-phosphate dehydrogenase) and rabbit Lamin 
A/C polyclonal antibodies were from Santa Cruz Biotecnology (Dallas, TX, 
USA). 
 
3.2 Cell cultures, transfection, human tissues and Western blotting 
Human gastric adenocarcinoma cell lines (AGS, MKN28, KATO III, NCI 
N87) and human embryonic kidney 293 (HEK293) cells were grown in 
DMEM-F12 and DMEM, respectively, supplemented with 10% heat 
inactivated FBS, 1% penicillin/ streptomycin and 1% L-glutamine at 37°C in 
a 5% CO2 atmosphere.  
AGS were transfected with 4 μg of vector pcDNA 3.1, pcDNA3.1-
flGKN1(His)6 encoding the full length GKN1 (flGKN1, containing the first 
20 amino acids leader peptide and His6-Tag sequence at the C-terminal) as 
already described [10]. The efficiency of transfection of gastric cancer cells 
with flGKN1 was always evaluated by a parallel transfection using EGFP 
vector as control. In general, after transfection, the average value of the ratio 
between number of green fluorescent cells/total number of cells was 0.5 ± 
0.1.  
Human gastric tissues were from patients with GC recruited at Hospital A. 
Cardarelli, Naples, Italy. All patients were interviewed regarding smoking 
habit, alcohol intake and chronic use of drugs. Hospital Pathologist 
performed the macro dissection of tumor and non-tumor tissues of GC 
patients during surgery. Gastric cancer was staged and graded according to 
the American Joint Committee on Cancer criteria [50]. The characterization 
of non-tumoral gastric mucosa was based on macroscopic aspects of normal 
compared with tumoral tissue as evaluated by the hospital pathologist [51], 
and from our previous work showing that GKN1 was highly expressed in 
gastric non-tumoral tissues but down-regulated or totally absent in GC tissues 
[3]. The study reported in the manuscript has been carried out in the frame of 
a research protocol entitled “Role of gastrokine 1 in gastric cancer” that has 
the approval from the Ethic Committee of the University of Naples Federico 
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II (Comitato Etico Università Federico II). The assigned protocol number of 
the study was 34/15 [51]. 
Proteins from cell extracts (about 20 μg) were analyzed by Western blotting 
using mouse anti-GKN1 at 1:500, rabbit anti-Histone H3 (tri methyl K9) at 
1:1000, rabbit anti-HDAC1 at 1:1000, mouse anti-SUV39H1 at 1:500, anti-
GAPDH at 1:1000 and rabbit anti-Lamin A/C at 1:1000 dilution. Detection 
was performed using the enhanced chemiluminescence detection kit 
(SuperSignal West Pico) following manufacturer’s instructions. Western blot 
band intensity was measured with ImageJ 1.46r software. 
 
3.3 RNA isolation and real-time qPCR  
Total RNA was extracted from normal and cancer human tissue or from 
using TRIzol reagent (Invitrogen) and quantified by Nanodrop (Thermo 
Scientific, Wilmington, DE). cDNA was synthesized using the reverse 
transcription kit from Roche Molecular Systems (Roche, Penzberg, 
Germany) according to the manufacturer’s protocol. GKN1 transcript levels 
was quantified using SYBR Green PCR MasterMix (Applied Biosystems) IQ 
SYBR green Supermix (Bio-Rad) on a CFX96 Real-Time System instrument 
(Bio-Rad) using using the following primers pairs:  
5'-CTTTCTAGCTCCTGCCCTAGC-3’;  
5’-TGGTTGCAGCAAAGCCATTT-3’. 
Real-Time qPCRs were performed in triplicate under the following 
conditions: 10 minutes at 95°C, followed by 40 cycles (15 seconds at 95°C 
and 1 minute at 60°C). The relative fold changes were calculated using the 2-
ΔΔCt method by the formula: 2-(sample ΔCt – control ΔCt), where ΔCt is the 
difference between the amplification fluorescent thresholds of the gene of 
interest and the internal reference gene (G6PD) used for normalization [52]. 
TaqMan MiRNA Assay kit (Applied Biosystems, Foster City, CA, USA) 
was used to detect the expression miRNAs (miR-544a, miR-1245b-3p) in 
DMSO or TSA treated cells lines. Briefly, 100 ng of total RNA was reversely 
transcribed (RT) at 16 ºC for 30 min, 42 ºC for 30 min and 85 ºC for 5 min in 
15 µl reaction volume. Two µl of RT product were used for PCR reaction in 
a final volume of 20 µl. The PCR reaction started with an initial denaturation 
step at 90 ºC for 10 min, followed by 40 cycles of 95 ºC for 15 sec and 60 ºC 
for 1 min. Small nucleolar RNA RNU6 (Applied Biosystems, Foster City, 
CA) was used for normalization. PCR reactions were performed in triplicate 
and fold changes were calculated using 2–ΔΔCT method, where ΔCt is the 
difference between the amplification fluorescent thresholds of the miRNA of 
interest and the RNA of RNU6. 
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3.4 Chromatin Immunoprecipitation assay 
Samples from normal and cancer human tissues were processed for 
chromatin immunoprecipitation (ChIP) assay. Cellular sospension was 
collected by centrifugation at 2000 rpm at 4°C for 10 minutes and then 
resuspended in 6× volume of cell lysis buffer [5 mM piperazine-N,N′-bis(2-
ethanesulfonic acid) (PIPES) pH 8.0, 85 mM KCl, 0.5% NP-40] plus 
phenylmethylsulfonyl fluoride (PMSF) (1 mM) and trypsin inhibitor (10 μg/ 
mL) as protease inhibitors. Cells were then incubated on ice for 15 minutes 
and lysed using a dounce several times. Nuclei were collected at 5000 rpm at 
4°C for 10 minutes and the pellet was resuspend in 5× volume of nuclei lysis 
buffer (50 mM TrisHCl pH 8.1, 10 mM EDTA, 1% SDS) plus the same 
protease inhibitors as the cell lysis buffer. The solution was incubate on ice 
for 20 minutes and subsequently freezed and thawed in liquid nitrogen 2 
times to aid in nuclear lysis. After centrifugation at 5000 rpm at 4°C for 10 
minutes, the obtained chromatin was sonicated according to the procedure 
described by Federico et al. 2009 [53]. Samples were subjected to IP with the 
following specific antibodies against histone modification anti-tri methyl K9-
Histone3, anti-acetyl H3 and the specific histone methyltransferase anti-
SUV39H1. For qRT-PCR, 2 μl aliquot of IP DNA (150 μl) were amplified 
with a set of three primers pairs (all primers are listed in the 5’ to 3’ 
direction); region A: F1, ggggtaggtttgg tgggagttgc, R1, 
atcacagctgaaaagccacgtgta; region B: F2, cgcccacagctttgactgggt, R2, 
tgccatgagccagtgtaccagga; region C: F3, tcctggtacactggctcatggca, R3, 
agcagtggacag aggagtaggca. GAPDH promoter amplicon was used as a 
negative control in all experiments (data not shown). IgGs were used as 
nonspecific controls, and input DNA values were used to normalize the 
values from quantitative ChIP samples. ChIP assay from AGS cells treated 
with dimethyl sulfoxide (DMSO) or TSA were processed as above reported. 
For each assay, about 5x106 AGS cells were used for chromatin preparation 
and IP. 
 
3.5 Treatment of gastric cancer cell lines with TSA 
AGS, MKN28 and KATO III cells were plated in 10 cm culture dishes and 
grown for 24 hours before drug treatment. The next day, about 8.8 x 106 cells 
were incubated in fresh culture medium containing a TSA/ DMSO solution 
up to a final concentration of 300 nM. Control cells were treated with an 
equivalent volume of DMSO. After 24 or 48 hours, cells were harvested and 
used either to evaluate the GKN1 mRNA and miR  expression by qRT-PCR 
or for ChIP assays. 
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3.6 Bioinformatic analysis 
For the identification of putative miRNA which can target GKN1 3’UTR, 5 
different software algorithms were used, namely TargetScan7.0 
(http://www.targetscan.org), miRanda (http://www.microrna.org), miRDB 
(http://mirdb.org), PITA (http://genie.weizmann.ac.il), and DIANA-microT-
CDS (v5.0) (http://www.microrna.gr/microT-CDS). Putative miRNA 
predicted by at least three algorithms have been selected for further studies.  
 
3.7 Plasmid construction and Luciferase Reporter Assay 
To understand the role of microRNAs in complex biological processes, it is 
important to experimentally assess the interaction between the four putative 
miRNAs and their targeting sequences in the 3’UTR of GKN1 mRNA. To 
these aim a luciferase reporter assay was performed. The full-length GKN1 
3’UTR (157bp) were amplified by PCR using AGS DNA with primer pairs 
containing XbaI and BamH1 sites. Oligonucleotide sequences were as 
follows:                                                                           
5'-ATCATTCTAGAGGATCCACAATTTTTTAAAGCCACTATGG-3';  
5'-ATCATTCTAGATGAATTCAATGCTAAATGATTTTAT-3'. 
The PCR products were cloned into the pGL3-control vector, downstream 
from the Firefly luciferase 3’UTR (Promega, Madison, WI, USA). The 
orientation of the inserted fragments was established by digestion and 
confirmed by sequencing. The pGL3 constructs with the reverse orientation 
were used as negative control. 
For luciferase assays, human HEK-293 cells were plated at in 24 well plates 
(40,000 cells/ well) 12 h before transfection. The pGL3 constructs (200 ng) 
were co-transfected with 100 nM pre-miRs (Ambion) and with the Renilla 
luciferase reporter plasmid (10 ng) as an internal control, using 
Lipofectamine 2000 (Invitrogen). Luciferase activity was measured at 48 h 
after transfection of IMR90 cells using a dual luciferase reporter assay 
(Promega) according to manufacturer’s instructions and performed on a 
20/20n Luminometer (Turner BioSystems, Sunnyvale, CA, USA). Relative 
luciferase activity was calculated by normalizing the firefly luminescence to 
the Renilla luminescence. All transfection experiments were done in triplicate 
and each experiment was repeated three times.  
 
3.8 Statistical analysis 
Statistical analysis was performed by two-tailed paired Student’s t-test using 
KaleidaGraph 4.1.1 software. Western blot band intensity was evaluated with 
ImageJ 1.41o software. Data were reported as means ± standard deviation 
(SD). The significance was accepted at the level of p < 0.05. 
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4. RESULTS 
 
4.1 Characterization of non-tumoral and tumoral tissues  
For this study, six gastric tissue specimens of paired samples of non-tumoral 
(N1–N6) and tumoral (T1–T6) human gastric tissues excised from the same 
patients during surgery were used. Tissue T1 was charactized by a well-
differentiated adenocarcinoma of intestinal type, T2 showed a severe 
dysplasia grade associated with a small area of intraglandular 
adenocarcinoma that was moderately differentiated, T3 and T6 exhibited a 
poorly differentiated adenocarcinoma of diffuse type, T4 showed a poorly 
differentiated adenocarcinoma of intestinal type, and T5 showed a 
moderately differentiated adenocarcinoma of intestinal type. 
The peritumoral areas of intestinal type GC presented a variable degree of 
gastric atrophy with diffuse intestinal metaplasia, while the peritumoral areas 
of diffuse type GC showed a variable degree of non-dysplastic inflammation. 
The clinicopathologic characteristics of GC patients are summarized in Table 
1.  
 
Table 1. Characteristics of Gastric Cancer Patients 
Variable Gastric Cancer 
patients (n = 6) 
Age at surgery (Y) 
Mean 
Range 
 
67 � 13  
45 – 78 
Sex ratio (M/F)  3/3 
Tumor type Intestinal 3, 
Diffuse 2 
Dysplasia 1 
Grade of differentiation Well 1, 
Moderate 2, 
Poor 3 
 
 
 
4.2 Expression levels of GKN1 in non-tumoral and tumoral tissues  
Subsequenly, the expression levels of GKN1 in non-tumoral (N1–N6) and 
tumoral (T1–T6) samples were analyzed. As reported in Figure 1 (panels A 
and C), compared with non-tumoral tissues, the expression profiles of GKN1 
evaluated by western blotting showed that in all tumoral samples a down-
regulation or an almost total absence of GKN1, as evaluated from the 
expression profile of GAPDH as a control (panels B and D) and based on the 
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densitometric analysis of GKN1 expression (Fig. 1E). Figure 1C also shows 
the expression profiles of GKN1 in positive control samples taken from 
healthy individuals undergoing sleeve gastrectomy (C1 and C2). 
To asses if the down-regulation of GKN1 also occurred at the 
transcriptional level, quantitative reverse transcription (qRT)-PCR on total 
RNA isolated from paired gastric non-tumoral and tumoral tissues were 
performed. As reported in Figure 1F, compared with non-tumoral tissues, a 
decrease of GKN1 mRNA levels in tumoral tissues was observed thus 
supporting the western blot findings.  
 
  
Figure 1. Expression levels of GKN1 in human gastric tissues. A and C. 
Western blot of tissue extracts analyzed in paired non-tumoral (N1-N6), 
tumoral (T1-T6) human gastric samples and samples taken from healthy 
individuals undergoing sleeve gastrectomy (C1 and C2), respectively, using 
mouse anti-GKN1 antibody. positive control E. Expression levels of GKN1 
protein in non-tumoral (N1-N6) and tumoral (T1-T6) paired samples 
evaluated from the densitometry of GKN1 bands normalized towards the 
corresponding densitometry of GAPDH bands B and D. F. qRT-PCR 
analysis. Total RNA was prepared from gastric tissues and analyzed by qRT-
PCR for GKN1 mRNA level compared to G6PD mRNA as reference sample. 
Data from three experiments are reported as mean values ± SD. 
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4.3 The down-regulation of GKN1 in GC was associated with 
H3K9triMe on the GKN1 gene promoter 
To highlight if epigenetic alteration was associated to the strong down-
regulation of GKN1 observed in the tumoral tissues analyzed, chromatin 
immunoprecipitation (ChIP) assays for the repressive trimethylation of 
histone 3 at lysine 9 (H3K9triMe) were performed. Using UCSC Genome 
Browser, a 600 bp promoter region of GKN1 gene including the 5’-
untranslated region (5’UTR) was identified and divided into three different 
segments (A, B, and C) of about 160 bp. The designed corresponding PCR 
primers (Fig. 2) used for ChIP assays revealed on the three DNA segments a 
significant increase in H3K9triMe modification in tumoral tissues compared 
with non-tumoral tissues. Figure 3 displays the results of an average of three 
independent experiments performed on six paired non-tumoral (N1–N6) and 
tumoral (T1–T6) specimens. 
 
 
  
 
Figure 2. 5’-region of GKN1 gene analyzed by ChIP assay and proposed 
gene expression regulation. The A, B and C regions of GKN1 gene 
promoter delimited by the corresponding primer pairs (F1-R1, F2-R2, F3-R3) 
are boxed. The length of the 5’UTR of GKN1 mRNA is indicated by double 
arrows. +1 indicates the position of the start codon. 
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Figure 3: H3K9triMe levels on human GKN1 gene promoter. Chromatin 
immunoprecipitation assays were performed on human non-tumoral (N1-N6) 
and tumoral (T1-T6) gastric samples, respectively. H3K9triMe enrichment 
relative to input is reported as 2ΔCt × 100, where ΔCt is the difference 
between CtInput and CtIP. All quantitative ChIP data were derived from 
three independent experiments, and for each experiment qPCR was 
performed in triplicate. * p<0.05, compared to corresponding control. 
 
 
4.4 The increase of H3K9triMe was associated with the recruitment 
and/or with the activation of  SUV39H1 on the GKN1 gene promoter 
Data from literature suggested that the H3K9triMe modification is  generally 
associated to a specific histone methyltransferase, the histone-lysine N-
methyltransferase SUV39H1, that trimethylates Lys-9 of histone H3 using 
mono-methylated H3 Lys-9 as a substrate [54]. Therefore, to asses the 
presence of this enzyme in the GKN1 promoter region a ChIP assays was 
performed. The result reported in Figure 4 clearly shows that compared with 
non-tumoral tissues, a significant increase in the binding of SUV39H1 to the 
GKN1 promoter region in tumoral samples was observed.  
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Figure 4. SUV39H1 levels on human GKN1 gene promoter. ChIP assays 
was performed on human non-tumoral N1-N6 (N) and tumoral T1-T6 (T) 
human gastric samples, respectively. SUV39H1 enrichment relative to input 
is reported as 2ΔCt× 100, where ΔCt is the difference between CtInput and 
CtIP. All quantitative ChIP data were derived from three independent 
experiments, and for each experiment qPCR was performed in triplicate. * 
p<0.05, compared to corresponding control. 
 
 
4.5 Expression levels of SUV39H1, HDAC1, and H3K9triMe in GC 
tissues 
Then, it was analyzed if there was a relationship between the expression 
levels of GKN1 and that of SUV39H1, histone deacetylase 1 (HDAC1), and 
H3K9triMe. As reported in Figure 5 (panels A and D), compared with non-
tumoral tissues (N1–N6), an increase in the expression of SUV39H1 in 
tumoral tissues (T1–T6), evaluated from the corresponding GAPDH western 
blot band intensity (Fig. 5, panels C and F), was observed. Similar behaviours 
for HDAC1 were seen in paired non-tumoral and tumoral gastric tissues (Fig. 
5, panels B and E). Regarding H3K9triMe, it was  possible to analyze its 
expression in the nuclear extracts of only one paired non-tumoral (N6) and 
tumoral (T6) sample. As shown in Figure 5G, compared with non-tumoral 
tissue, tumoral tissue showed higher level of H3K9triMe expression as 
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determined by the western blot band intensity ratio with respect to that of 
lamin A/C (Fig. 5H).  
The expression levels of SUV39H1 and HDAC1 were next evaluated in 
healthy sleeve gastrectomy specimens (C1 and C2) (Fig. 5, panels D and E). 
In these cases, expression levels appeared similar to those of non-tumoral 
tissues (N4–N6). 
 
  
 
Figure 5. Expression levels of SUV39H1, HDAC1 and H3K9triMe in 
human gastric tissues. SUV39H1, HDAC1 expression in human non-
tumoral (N) and tumoral (T) cell extracts (panels A-F) and H3K9triMe 
expression in nuclear extracts (panels G-H) was assessed by Western blot 
with the specific antibodies. Relative expression of SUV39H1, HDAC1 in 
sample tissues is reported as band intensity ratio with that of the 
corresponding GAPDH whereas that of H3K9triMe is shown as band 
intensity ratio with that of the corresponding lamin A/C. 
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4.6 Expression levels of SUV39H1, HDAC1, and H3K9triMe in cell lines 
The expression levels of SUV39H1, HDAC1, and H3K9triMe proteins was 
also evaluated in GC cell lines. Because of the lack of a non-tumoral gastric 
cell line, we analyzed protein expression in GKN1-transfected and non-
transfected GC cells (AGS) and in an additional non-transfected gastric 
cancer cell line (NCI-N87). As shown in Figure 6, compared with non-
transfected cells, AGS cells transfected with GKN1 demonstrated lower 
expression levels of SUV39H1 (Fig. 6I), HDAC1 (Fig. 6J), and H3K9triMe 
(Fig. 6K) as determined by the western blot band intensity ratio with respect 
to that of lamin A/C (Fig. 6L).  
 
  
 
Figure 6. Expression levels of SUV39H1, HDAC1 and H3K9triMe in 
human gastric cell lines. Protein expression in gastric cancer cell lines 
(panels I-L) was assessed by Western blot with the specific antibodies on 
nuclear extracts of AGS cells (lane 1), AGS cells transfected with flGKN1 
(lane 2) and NCI-N87 cells (lane 3). Relative expression of SUV39H1, 
HDAC1 and H3K9triMe is reported as band intensity ratio with that of the 
corresponding lamin A/C. 
 
 
4.7 Trichostatin A induced the up-regulation of GKN1 mRNA in GC cell 
lines 
To further understand the effect of epigenetic modifications on GKN1 down-
regulation, the possible role of histone acetylation was investigated. MKN28, 
AGS, and KATO III GC cell lines were treated with trichostatin A (TSA), an 
inhibitor of histone deacetylases (HDACs), and GKN1 mRNA levels were 
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evaluated by qRT-PCR. As reported in Figure 7, treatment of AGS cells with 
TSA for 24 h led to an increase in GKN1 mRNA expression of about 28-fold 
compared with untreated cells, whereas no effect was observed in MKN28 
and KATO III cells. TSA treatment for 48 h increased GKN1 mRNA 
expression by around 50-, 160- and 110-fold in MKN28, AGS, and KATO 
III cells, respectively. However, the increase in the GKN1 mRNA levels were 
not associated with the re-expression of the protein as evaluated by western 
blotting (data not shown). 
 
  
 
Figure 7. TSA induced the expression of GKN1 mRNA in gastric cancer 
cell lines. qRT-PCR analysis of GKN1 mRNA in MKN28, AGS and KATO 
III gastric cancer cell lines after TSA treatment of the cells for 24 and 48 
hours. G6PD was used as internal standard for normalization The relative 
expression of GKN1 was evaluated using as control cells treated with DMSO. 
Data from a representative experiment are reported as mean values ± SD. * 
p<0.05. 
 
 
4.8 Trichostatin A induced in GC cell line the down-regulation of  
H3K9triMe and up-regulation of H3 acetylation 
The up-regulation of GKN1 mRNA observed in TSA-treated AGS cell line 
suggested the use of these cells as a positive control to confirm the results 
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obtained in human gastric tissues in a cellular gastric model. As reported in 
Figure 8, a ChIP assay showed that up-regulation of GKN1 mRNA in AGS 
cells after TSA treatment was associated with a reduction of the H3K9triMe 
repressive modification (Fig. 8 A). This result confirmed what found in 
gastric tissues, and revealed an increase of H3-acetylation-activating 
modification in the same three regions of the GKN1 promoter analyzed 
earlier (Fig. 8B). 
 
 
  
 
Figure 8. TSA induced in AGS cells decreased levels of H3K9triMe and 
increased levels of H3 acetylation. Levels of H3K9triMe (A) and Levels of 
H3 acetylation (B) determined by ChIP assays on AGS cells not treated (-
TSA) and treated with TSA (+TSA). H3K9triMe and H3 acetylation 
enrichment relative to input are reported as 2ΔCt × 100, where ΔCt is the 
difference between CtInput and CtIP. All quantitative ChIP data were derived 
from three independent experiments, and for each experiment, qRT-PCR was 
performed in triplicate. * p<0.05, compared to corresponding control. 
 
 
4.9 Bioinformatic analysis for miRNAs targeting GKN1 3’UTR 
Although GKN1 mRNA was strongly up-regulated in castric cancer cell lines 
after TSA treatment, the presence of the protein as evaluated by Wester 
blotting was still undetectable. Therefore, it was hypothesized the occurrence 
of a post-translation regulation of GKN1 expression mediated by miRNAs. 
To search for putative miRNAs that could target the 3’UTR of GKN1 
mRNA, in silico analyses were performed using 5 different algorithms 
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(TargetScan 7.0, miRDB, miRanda, PITA, and DIANA-microT-CDS v5.0). 
Putative miRNAs were selected following a level of stringency that was 
based on the intersections of ≥3 different algorithms (Figure 9). This allowed 
evidentiate 4 putative miRNAs: hsa-miR-1245b-3p (3’-
AUAUCCGGAAAUCUAGUAGACU-5’, 22 nts), hsa-miR-186-5p (3’-
UCGGGUUUUCCUCUUAAGAAAC-5’, 22 nts), hsa-miR-325 (3’-
UGUGAAUGACCUGUGGAUGAUCC-5’, 23 nts), hsa-miR-544a (3’-
CUUGAACGAUUUUUACGUCUUA-5’, 22 nts); the underlined sequence 
represents the miRNA seed region. Figure 10 shows the nucleotide sequence 
of GKN1 3’UTR and the corresponding segments where the identified 
miRNAs form base pairing.  
 
 
 
  
 
 
Figure 9. Venn diagram showing the algorithms intersection highlighting 
miRNAs targeting GKN1 3’UTR. miRNAs population of each algoritm is 
given in parenthesis.  
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Figure 10. GKN1 3’UTR and miRNAs annealing regions. Nucleotide 
sequence of the 3’UTR of GKN1 mRNA showing the corresponding 
miRNAs target sequences (boxed).  
 
 
4.10  GKN1 3'UTR is direct target of hsa-miR-544a and miR-1245b-3p 
The functional studies were performed using constructs containing the GKN1 
3’UTR (WT) and GKN1 reverse 3’UTR (MUT), as negative control, cloned 
downstream of the luciferase genes. These report plasmids were co-
transfected in presence of premiR negative control (miR-SCR) or the 4 
premiRs in HEK-293 cells and the luciferase activity was assessed. As shown 
in Figure 11, over-expression of miRNAs resulted in a significant inhibition 
of the activity of the reporter constructs bearing the wild-type (WT) 3’UTRs 
of GKN1 gene when compared with miR-SCR-transfected cells only for miR-
544a and miR-1245b-3p (Fig. 11C, D) whereas for miRNA-186-5p and miR-
325, no effect was instead observed (Fig. 11A, B].   
The transfection of the constructs containing the inverted 3’UTR regions 
(MUT) abolished the effect of miR-544a and miR-1245b-3p. These results 
indicated that GKN1 3’UTR is a direct target of miR-544a and miR-1245b-
3p. 
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Figure 11. Validation of putative miRNAs by luciferase assay in HEK293 
cells. The luciferase constructs bearing WT or inverted (MUT) GKN1 3’UTR 
were co-transfected in presence of premiR negative control (miR-SCR) or the 
4 premiRs in HEK-293 cells. Renilla luciferase was used as an internal 
control. Dual luciferase assays were performed as described in Materials and 
Methods. Triplicate transfection ratio (±SD) firefly/Renilla luciferase activity 
were averaged and expressed as percentage of the corresponding 
transfections with miR-SCR control. *p < 0.05. 
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4.11 TSA-induced up-regulation of GKN1 mRNA is accompained in GC 
cell lines by up-regulation of miR-544a 
To assess the possible involvment of miRNAs in the post-translation 
regulation of GKN1 expression, it was evalueted the expression level of miR-
544a and miR-1245b-3p in MKN28, AGS and KATO III cell lines after TSA 
treatment by TaqMan MiRNA Assay. The results showed an increase of 
miR-544a expression of about 20-, 140- and 60-fold in MKN28, AGS, and 
KATO III cells, respectively, compared with untreated cells (Fig. 12A); the 
expression of 1245b-3p was detectable only in AGS cells with an increase of 
about 7-fold (Fig. 12B), whereas no effect was observed in MKN28 and 
KATO III cells. 
These results suggest that the up-regulation of miR-544a could represents 
one of the leading cause of the GKN1 translational repression. 
 
 
 
  
 
Figure 12. Expression level of miR-544a and miR-1245b-3p in TSA-
treated cell lines. qRT-PCR analysis of miR-544a (A) and miR-1245b-3p 
(B) in MKN28, AGS and KATO III gastric cancer cell lines after TSA 
treatment of the cells for 48 hours. RNU6 was used as internal standard for 
normalization The relative expression was evaluated using as control cells 
treated with DMSO. Data from a representative experiment are reported as 
mean values ± SD. * p<0.05. 
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5. DISCUSSION 
 
One of key risk factor in the development of many types of cancers harbour 
from tissues inflammation and in particular, stomach chronic inflammation 
could lead to the histopathologic progression of chronic gastritis across 
gastric atrophy, intestinal metaplasia, dysplasia, and finally GC [55]. A major 
step in the initiation and development of GC is Helicobacter pylori infection 
of the gastric mucosa and the consequent chronic inflammation [56]. 
Hypermethylation of promoters of tumor-related genes is quite often detected 
in premalignant gastric lesions [57]. These findings suggest a relationship 
with the induction and or promotion of GC [58, 59]. In fact, aberrant DNA 
methylation is one of the leading inactivating mechanisms of tumor 
suppressor genes frequently associated with H. pylori infection [60, 61].   
It is already well estabilished that the expression of gastrokine 1 (GKN1) 
decreases throughout the progressive stages of neoplastic transformation. 
Earlier investigations performed on GC tissues showed no CpG hyper-
methylation of the GKN1 promoter [48] and altered GKN1 expression 
associated with the severity of gastritis and DNA methylation in non-
neoplastic gastric mucosa [62]. Other studies showed that GKN1 expression 
in AGS cells induced endogenous micro RNA (miR)-185 that directly targets 
the epigenetic effectors DNA (cytosine-5)-methyltransferase 1 (DNMT1) and 
histone-lysine N-methyltransferase enzyme (EZH2). In particular, the histone 
acetyl transferase Tip60 was found to be up-regulated and HDAC1 to be 
down-regulated in an miR-185-independent manner, thus inducing cell cycle 
arrest by regulating cell cycle proteins in GC cells [63]. However, the exact 
relationship between gastritis and GKN1 expression was not evaluated.   
In this thesis, the possible causes of GKN1 gene inactivation have been 
investigated by evaluating if other possible epigenetic mechanisms could be 
involved in this process. Because DNA methylation, histone deacetylation, 
and histone H3 methylation at lysine 9 are the three best-characterized 
covalent modifications associated with a repressed chromatin state, the 
attention was focused on these modifications [64, 65]. For the first time it has 
been shown that a mechanism comprising histone modifications appears to be 
involved in the dysregulation of GKN1 transcription in GC. In fact, by using 
ChIP assays, comparing human non-tumoral tissues with corresponding 
tumoral ones, it was revealed an increase of the repressive histone 
modification H3K9triMe (Fig. 3) associated by recruitment of the specific 
histone methyltransferase SUV39H1 (Fig. 4; Fig. 5A, D) in tumoral tissues. 
SUV39H1 and H3K9triMe upregulation both at transcriptional and 
translational level has been demonstrated in several cancers therefore, 
SUV39H1 and H3K9triMe have important roles in cancer development and 
progression. Moreover, the pharmacological inhibition of SUV39H1 
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represents a promising therapeutic approach for cancer treatment [66, 67]. 
The present thesis documents in gastric carcinoma the overexpression of 
Suv39H1 and histone tri-methylated H3K9. 
Interestingly, the results obtained showed that eventhough the H3K9triMe 
enrichment levels observed in the six human specimens appeared 
quantitatively different, the promoter region of GKN1 gene where this 
modification was mostly enriched was the same in all samples (region B). No 
significant difference in H3K9triMe in non-tumoral gastric tissues was 
instead observed compared with tumoral ones. This observation suggests a 
correlation with the expression of GKN1 protein shown in Figure 1. In fact, 
the H3K9triMe enrichment observed by ChIP assay (Fig. 3) was associated 
with tumoral samples in which strong down-regulation of GKN1 expression 
was observed. The important role of H3K9triMe in GC was also supported 
by the finding that H3K9 trimethylation positively correlates in gastric 
carcinoma with tumor stage, lymphovascular invasion, and cancer recurrence 
whereas higher levels of H3K9 trimethylation correlate with poor survival 
[38]. 
One of the main determinants of chromatin structure is given by histone 
acetylation [68] that can be regulated dynamically through the involvement 
of transactivating factors with intrinsic histone acetylase activity or through 
the recruitment of deacetylase complexes that repress gene expression [69]. 
HDAC1 is in fact up-regulated in many cancer cell lines and tissues [70], 
including GC, at both the transcriptional and translational levels [71]. The 
findings here reported are in agreement with these aspects (Fig. 5) and imply 
that increased HDAC1 expression causes histone hypoacetylation and the 
silencing of several tumor suppressor genes in GC. 
The model hereafter reported could describe the mechanisms by which 
H3K9triMe acts on the GKN1 promotor (Fig. 13) mediated by SUV39H1. A 
transcription factor functions as a negative regulator by recruiting SUV39H1 
and HDACs on the GKN1 promoter to induce histone deacetylation and 
methylation, thus resulting in GKN1 repression. 
 
  
Figure 13. Proposed GKN1 gene expression regulation. Scheme 
showing the proposed mechanism of histone/SUV39H1 actions on GKN1 
gene promoter. 
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This model is in agreement with recent findings showing that restoration of 
GKN1 protein suppressed GC cell growth through an miRNA-mediated 
mechanism for DNA epigenetic modification [63]. Therefore, the loss of 
GKN1 function contributes to malignant transformation and the proliferation 
of gastric epithelial cells in gastric carcinogenesis. 
On the bases of the above findings, it was then investigated whether 
underacetylation could contribute to GKN1 transcriptional inhibition using 
TSA to increase general histone acetylation in an attempt to bypass the 
inhibitory effects of DNA methylation. Because TSA in the absence of 
cytotoxicity can affect the cell cycle, regulates cell differentiation, induces 
apoptosis, and inhibits cell migration [72-74], to reduce the possible 
inhibition of cell proliferation [75] milder experimental conditions (TSA, 90 
ng/ml; time of treatment, 24 and 48 h) were used. 
Under these same experimental conditions, TSA was found to reduce AGS 
cell viability by less than 10% [76], and to inhibit in a dose-dependent 
manner MKN28 cell growth up to a concentration of 500 ng/ml [77]. Here, 
treatment of GC cell lines MKN28, AGS, and KATO III with TSA strongly 
increased GKN1 mRNA expression (Fig. 7), thus suggesting that histone 
deacetylation represents an important mediator of GKN1 repression 
associated with DNA methylation. In fact, treatment of AGS cells with TSA 
led to a reduction of H3K9triMe and an increase of histone acetylation (Fig. 
8). Because histone acetylation is a fundamental regulatory mechanism for 
controlling gene accessibility, the results obtained indicate that histone 
methylation is a unique mechanism for establishing local histone 
deacetylation, and generating maintainable epigenetic chromosomal states. 
However, it should be considered that in the experimental condition used, 
the up-regulation of GKN1 mRNA level was still very low because the cycle 
numbers required for its amplification resulted of about 10-fold lower than 
those required for the amplification of housekeeping glucose-6-phosphate 
dehydrogenase (data not shown). Neverthless, no GKN1 protein re-
expression was detected under these conditions by Western blotting. This 
finding could have been caused by proteosome-mediated degradation of the 
GKN1 protein. To ascertain this possibility, AGS cells were treated with 
proteosome inhibitor (MG132). No GKN1 expression was observed (not 
shown). This finding suggested the presence of further regulation at the 
translational level, perhaps by mechanisms mediated by miRNAs, resulting 
in translational repression and gene silencing. For example, in a recent work, 
it has been reported that miRNA-544 directly targets the 3’UTR of the 
newly-identified tumor suppressor gene IRX1, whose hypermethylation 
decreases expression of the protein in GC [78]. Therefore, miRNAs and 
promoter hypermethylation are important epigenetic mechanisms for 
transcriptional inactivation of tumor suppressors. In fact, miRNAs are post-
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transcriptional regulators that by interacting with their targets in the 3’UTR 
of transcripts lead to either mRNA degradation or to translation inhibition. 
For the identification of putative miRNA which can targets GKN1 3’UTR, 
a bioinformatic approach was undertaken by analyzing 5 different software 
algorithms. The intersection of ≥3 programs resulted in a list of 4 potential 
miRNAs: hsa-miR-1245b-3p, hsa-miR-186-5p, hsa-miR-325, hsa-miR-544a. 
To verify if the selected miRNAs were able to target the 3’UTR of GKN1 
mRNA, a luciferase reporter assay was performed. The results of these 
experiments showed that GKN1 3’UTR was mainly a direct target of hsa-
miR-544a and to a lower extent to miR-1245b-3p (Fig. 11). 
On the bases of these results, it was then tryied to highlight the possible 
involvment of these miRNAs in the post-translation regulation of GKN1 
expression. Therefore, it was evaluated the expression level of miR-544a and 
miR-1245b-3p in MKN28, AGS and KATO III gastric cancer cell lines after 
TSA treatment in which we observed a strong increase of GKN1 mRNA 
expression that was not accompained by the expression of the protein. 
Compared with untreated cells, the results showed an evident up-regulation 
of miR-544a expression of about 20-, 140- and 60-fold in MKN28, AGS, and 
KATO III cells, respectively. The expression of miR-1245b-3p was instead 
detectable only in AGS with an increase of about 7-fold only, whereas no 
effect was observed in MKN28 and KATO III cells. Therefore, one might 
postulate that the up-regulation of miR-544a could be the cause of GKN1 
translational repression, thus suggesting its potential role as biomarker and as 
therapeutic target in GC patients. The data here presented are hopeful since 
miR-544a has been shown to play an important role in gastric cancer by 
inducing epithelial-mesenchymal transition (EMT) [79]. 
These findings suggest that epigenetic mechanisms leading to the 
inactivation of GKN1 play a key role in the multi-step process of gastric 
carcinogenesis and would provide an essential starting point for the 
development of new therapeutic strategies based on epigenetic targets for 
alternatives gene. 
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6. CRITICISMS AND  FUTURE PERSPECTIVES 
One first criticism of the present study regards the number of GC speciments 
used. Although the results obtained on six GC patients were similar, to be 
confident that a mechanisms underlyning GKN1 gene silencing is based on 
the up-regulation of histone methylation H3K9triMe by SUV39H1 and 
deacetylation mediated by HDAC1, a larger number of samples should be 
analyzed. However, this aspect is not easy to afford because the difficulty in 
the recruitment of GC patients, in the quality and quantity of tissues 
specimens that can be obtained after surgery and in the intrinsic difficulty of 
the ChIP assay experimental procedure. In fact, the number of experiments 
carried out were much higher with respect to those here reported and not in 
all of them the same reproducibility was observed. Nevertheless, it has been 
already planned with Hospital Partner the recruitment of a new set of samples 
in order to enlarge the statistical significance of the data obtained. 
It was also tried to clarify the controversial behaviour of H3K4triMe that 
with respect to the up-regulation of H3K9triMe it should be instead dow-
regulated. However, there are several reports in which is described that 
H3K4triMe remains almost unchanged during inactivation of tumor 
suppressor genes. In agreement to what reported in these works, ChIP assay 
performed on two pairs non-tumoral and tumoral samples confirmed in these 
cases no variations in the H3K4triMe levels. 
It was also searched for possible transcription factors that could have been 
involved in GKN1 positive or negative transcription regulation. Literature 
data suggested to assay the expression profile of RUNX3 and CBX7 by WB. 
Using the collection of paired non-tumoral and tumoral GC tissues 
specimens, not substantial differences were observed. Also ChIP assay 
performed for RUNX3 did not shown the presence of this factor on the 
GKN1 promoter region.  
Another important criticism concerning the project is the lack of a normal 
gastric cell line expressing GKN1. Although there are in the world two 
research groups that claim to possess this cell line, no success was achieved 
when these cells were received since no GKN1 expression was detected.  For 
this reason, in order to study the functions of miRNAs we need an in vitro 
model of the gastric mucosa. 
Therefore, I am now developing a method to culture normal human gastric 
epithelial cells from endoscopic biopsies, using enzymatic digestion to isolate 
cells. 
Human gastric epithelial cells have been difficult to maintain in culture for 
prolonged periods of time. In order to increase the life span of normal human 
gastric epithelial cells in culture, I plan to transfect these cells with the SV40 
Large T-Ag in order to immortalize them. At the moment, several trials to 
amplify a primary culture are in progress. In fact, having available a gastric 
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cell line expressing GKN1, functional effects of the selected miRNAs by 
treating the gastric cells with the corresponding premiR could be evaluated 
and a reduction in the expression level of GKN1 should be observed. 
However, some criticisms linked to the identification of miR-544a and 
miR1245b-3p as possible negative regulator of GKN1 expression should be 
taken in consideration. 
First of all, the up-regulation of miR-455a observed following treatment of 
gastric cancer cell line might not be directly induced by the increase of GKN1 
mRNA but to TSA treatment of the gastric cells. In fact, although TSA was 
used at mild concentration, it might had a general effect on histone 
deacethylation of the promoter regions of other genes and thus somehow 
induced the up-regulation of miRNAs. However, it must be pointed out that 
the increase of GKN1 mRNA and the up-regulation of miRNA-544a in the 
three cell lines show a similar behaviour. This observation might suggest that 
the trasfection of the gastric cancer cell lines after TSA treatment with the 
corresponding anti-miRNAs should possibly lead to the re-expression of the 
protein. 
Comparison of the expression levels of miR-544a and miR-1245b-3p in 
paired non-tumoral and tumoral gastric tissues also represents an important 
experimental approach. In particular, the evaluation should be carried out in a 
large number of samples and in association with the histopathologic 
characteristic of the gastric cancer tissues. In fact, miRNA up- or down-
regulation might be very sensitive to the state and progression of the disease. 
In these circumstance, it might also function as possible tumor marker 
especially when its established up-regulation is associated to a tumoral stage. 
In preliminary experiments, assaying the expression level of miR-544a and 
miR-1245b-3p, it was found that compared to the normal gastric tissue, miR-
544a was found up-regulated in a sample from a patient owing intestinal 
metaplasia. The increase observed was about  3-fold compared to the control 
thus suggesting that this miRNA might be up-regulated during a particular 
stage of gastric cancer progression. Of coarse, this encouraging observation 
should be confirmed by analyzing other well characterized tissues.   
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7. CONCLUSIONS 
In conclusion, I found that GKN1 expression was significantly reduced in 
several specimens from patients with gastric carcinoma showing dysplasia 
and tumor gastric mucosa, and that GKN1 down-regulation was inversely 
correlated with the recruitment on the GKN1 promoter of H3K9triMe and 
Suv39H1. GKN1 expression in tumoral tissues was also associated with an 
overall increase of the expression profiles of H3K9triMe, Suv39H1, and 
HDAC1 proteins. These findings strongly suggested that that epigenetic 
mechanisms leading to the inactivation of GKN1 play a key role in the multi-
step process of gastric carcinogenesis. The results obtained can be considered 
relevant and reliable since they were obtained in vivo on human specimens. 
Nevertheless it will be necessary to confirm them in a larger number of 
samples. 
TSA-mediated down-regulation of H3K9triMe and up-regulation of H3 
acetylation observed in gastric cancer cells supported the obtained data 
whereas, TSA-induced increase of GKN1 mRNA not accompained by the 
expression of the protein suggested a miRNAs mediated post-translation 
regulation. Of coarse, the identification of miR-544a and perhaps miR-
1245b-3p as additional possible regulators of GKN1 expression in GC should 
be better characterized. This will enable obtain a greater understanding of 
these mechanisms and to determine whether they are involved in the 
development and progression of GC. 
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8. APPENDICES 
8.1 Example of qRT-PCR calculation for H3K9triMe Chip assay 
performed on the A, B and C regions of the GKN1 gene promoter 
Patient n. 2 
Region A  Dct 2-Dct 2-Dct x100 
N Input N IgG N Igg-N Input  
27,42200216 32,90889809 5,486895927 0,02229871 2,229871017 
27,24634822 32,57791753 5,331569307 0,024833488 2,483348753 
27,35886712 33,01756375 5,658696633 0,019795322 1,97953223 
N Input N Met N Met-N Input   
27,42200216 36,11472032 8,692718158 0,002416746 0,241674646 
27,24634822 36,25444646 9,008098241 0,001942192 0,194219229 
27,35886712 34,23138517 6,872518054 0,008534261 0,853426099 
T Input T IgG T Igg-T Input   
27,57182797 44,97860592 17,40677795 5,7549E-06 0,00057549 
28,09594252 44,97860592 16,8826634 8,27584E-06 0,000827584 
27,35157109 44,97860592 17,62703483 4,94008E-06 0,000494008 
T Input T Met T Met-T Input   
27,57182797 32,74959045 5,177762478 0,027627283 2,762728347 
28,09594252 33,67432301 5,578380492 0,020928598 2,092859841 
27,35157109 32,5944488 5,242877707 0,026408063 2,640806295 
 
 
Region B  Dct 2-Dct 2-Dct x100 
N Input N IgG N Igg-N Input   
27,9044421 33,02732687 5,122884767 0,028698422 2,869842222 
27,76507613 33,25170743 5,486631302 0,022302801 2,230280067 
28,05589741 33,72531676 5,669419356 0,01964874 1,964874045 
N Input N Met N Met-N Input   
27,9044421 33,81718792 5,912745814 0,016599162 1,659916161 
27,76507613 35,04311039 7,278034263 0,006443078 0,644307783 
28,05589741 34,27208766 6,216190248 0,013450557 1,345055723 
T Input T IgG T Igg-T Input   
28,65401001 34,58360595 5,929595936 0,016406418 1,640641757 
28,36326492 34,03490014 5,671635228 0,019618585 1,961858462 
28,40308657 35,02161751 6,618530936 0,010177091 1,017709108 
T Input T Met T Met-T Input   
28,65401001 32,65128316 3,99727315 0,062618243 6,261824347 
28,36326492 32,86650539 4,503240471 0,04409502 4,409501967 
28,40308657 32,56866913 4,165582556 0,055723027 5,572302712 
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Statistical evaluation of the results with Student-t-test using 
KaleidaGraph 4.1.1 software. 
 
Region C  Dct 2-Dct 2-Dct x100 
N Input N IgG N Igg-N Input   
28,29850371 34,08240063 5,783896927 0,018149871 1,81498706 
30,17438951 33,25085767 3,076468154 0,118547065 11,85470647 
27,55576253 34,37842784 6,822665304 0,008834319 0,883431932 
N Input N Met N Met-N Input   
28,29850371 36,91310832 8,614604615 0,002551206 0,255120649 
30,17438951 36,0490027 5,874613189 0,017043752 1,704375243 
27,55576253 37,56824645 10,01248392 0,000968149 0,096814857 
T Input T IgG T Igg-T Input   
28,34489232 38,52636523 10,18147291 0,000861135 0,086113503 
28,09345669 38,52636523 10,43290854 0,000723405 0,072340514 
28,2191745 38,52636523 10,30719072 0,000789271 0,07892715 
T Input T Met  T Met-T Input   
28,34489232 33,48637577 5,141483446 0,028330828 2,833082754 
28,09345669 33,26998208 5,176525388 0,027650984 2,765098361 
28,2191745 33,39080956 5,171635055 0,027744872 2,774487176 
Region A   Region B   Region C   
Student t Test for paired 
data 
Student t Test for paired 
data Student t Test for paired data
Group 1: N 
IgG   Group 1: N IgG   Group 1: N IgG   
Group 2: N 
Met   Group 2: N Met   Group 2: N Met  
 
Group 
1 Group 2  
Group 
1 Group 2  
Group
1 Group 2 
Count 3 3 Count 3 3 Count 3 3 
Mean 
2,2309
2 
0,000632
361 Mean 2,355 1,54007 Mean 
4,8510
4 0,0791271 
Variance 
0,0634
586 3,02E-08 Variance 
0,2164
08 
0,23044
1 Variance 
37,005
4 4,75E-05 
Std. Dev. 
0,2519
1 
0,000173
908 Std. Dev. 
0,4651
97 
0,48004
2 Std. Dev. 
6,0832
1 0,00688867 
Std. Err 
0,1454
4 
0,000100
406 Std. Err 
0,2685
81 
0,27715
3 Std. Err 
3,5121
4 0,00397718 
         
Mean 
Difference 
2,2302
9  Mean Difference
0,8149
29  
Mean 
Difference 
4,7719
1  
Degrees of 
Freedom 2  
Degrees of 
Freedom 2  
Degrees of 
Freedom 2  
t Value 15,345  t Value 2,8581  t Value 1,3574  
t Probability 
0,0042
2  
t 
Probability 0,1037  t Probability 0,3075  
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  Region A   Region B   Region C   
Student t Test for paired data 
Student t Test for paired 
data 
Student t Test for paired 
data 
Group 1: T IgG   Group 1: T IgG   Group 1: T IgG   
Group 2: T Met   Group 2: T Met   Group 2: T Met   
        
 Group 1 
Group 
2  Group 1 Group 2  Group 1 Group 2 
Count 3 3 Count 3 3 Count 3 3 
Mean 
0,42977
3 2,4988 Mean 
1,2164
3 5,41454 Mean 
0,6854
37 2,79089 
Variance 
0,13517
4 
0,1273
06 Variance 
0,2702
74 0,87644 Variance 
0,7849
42 
0,0013572
4 
Std. Dev. 
0,36766
1 
0,3567
99 Std. Dev. 
0,5198
79 0,936184 Std. Dev. 
0,8859
69 0,0368408 
Std. Err 
0,21226
9 
0,2059
98 Std. Err 
0,3001
52 0,540506 Std. Err 
0,5115
15 0,02127 
         
Mean 
Difference -2,06902  
Mean 
Difference 
-
4,19812  
Mean 
Difference 
-
2,10545  
Degrees of 
Freedom 2  
Degrees of 
Freedom 2  
Degrees of   
Freedom 2  
t Value -9,0633  t Value -17,349  t Value 
-
4,0245  
t Probability 0,01196  t Probability 
0,0033
06  
t 
Probability 
0,0505
5  
 
 
 
  
 
Graph of the results included in the Fig. 2 of the thesis 
Appendices 
 
 37
8.2 Example of qRT-PCR calculation for GKN1 mRNA expression 
levels performed on AGS cells before and after treatment with TSA 
 
 
 
 
Statistical evaluation of the results with Student-t-test using 
KaleidaGraph 4.1.1 software. 
 
 
 
 
 
 
 
Sample cDNA2 G6PD CDNA2/G6PD Dct 2-Dct 
      
AGS DMSO 35,45140035 23,58581968 11,86558068 0 1 
 35,00294388 23,57034208 11,43260179 0 1 
 35,07313792 23,68654877 11,38658916 0 1 
AGS 24h 33,7267492 26,76284773 6,963901462 -4,901679216 29,89182789 
 33,18307826 26,38631757 6,796760685 -4,635841109 24,86149434 
 33,00561147 26,52359121 6,482020256 -4,904568901 29,95176054 
AGS 48h 36,39986532 32,44236017 3,957505142 -7,908075536 240,1972021 
 37,02686188 32,20084112 4,826020765 -6,606581029 97,44937511 
 36,34090629 32,24629255 4,094613739 -7,291975418 156,712388 
AGS 24   AGS 48   
Student t Test for paired data  Student t Test for paired data  
Group 1: - TSA  Group 1:  - TSA  
Group 2:  + TSA 24h  Group 2:  + TSA 48h  
      
 Group 1 Group 2  Group 1 Group 2 
Count 3 3 Count 3 3 
Mean 1 28,235 Mean 1 164,786 
Variance 0 8,53645 Variance 0 5143,13 
Std. Dev. 0 2,92172 Std. Dev. 0 71,7156 
Std. Err 0 1,68686 Std. Err 0 41,405 
      
Mean Difference -27,235  Mean Difference -163,786  
Degrees of 
Freedom 
2  Degrees of Freedom 2  
t Value -16,145  t Value -3,9557  
t Probability 0,003814  t Probability 0,05037  
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8.3 Example of WB band densitometry evaluation using ImageJ 1.14o 
software  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WB were analyzed using ImageJ to calculate the ratio of sample band peak areas with that of 
the corresponding control 
 
Graph of the results included in the Fig. 6 of the thesis 
H3K9triMe 
 
 
Peak area 
 
 
1,78E+04 
6,71E+03 
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Lamin A/C  
Peak area 
 
 
1,96E+04 
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